Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +15

Stryker Corp stock steadies as RBC flags limited upside for 2026

AI-generated analysis

📉 Stryker Corp stock is down nearly 20 percent year-to-date as of September 17, 2026, trading around USD 280.

🛡️ RBC Capital Markets identifies a recent cyberattack and softer demand in orthopedics and peripheral vascular lines as key reasons for the transition phase.

📈 Analysts maintain an average price target of USD 374.88, suggesting roughly 31.65 percent potential upside if medium-term growth resumes.

🔮 Prospects are expected to improve in 2027 as hospital equipment budgets and surgery schedules become more predictable.

📊 The stock holds a Buy rating from 28 analysts despite the cautious near-term outlook for the remainder of 2026.

💰 Stryker Corp has a market capitalization of approximately USD 106 billion in the healthcare equipment sector.

Bullish Signals
  • Analysts maintain an overall Buy rating with 28 covers, indicating confidence in the company's long-term strategy despite current headwinds.
  • The average analyst price target stands at USD 374.88, implying a potential upside of approximately 31.65 percent from current levels.
  • Shares have gained about 4.17 percent over the last five trading days, showing resilience and modest recovery momentum.
Risk Factors
  • Stryker Corp stock has declined nearly 20 percent year-to-date, reflecting significant pressure on the share price since the start of 2026.
  • RBC Capital Markets flags limited upside for the remainder of 2026 due to a recent cyberattack impacting operations and security posture.
  • The company is facing softer demand in key product lines, specifically orthopedics and peripheral vascular devices.
Full Analysis
Stryker Corp stock has stabilized near USD 280 on September 17, 2026, following a year-to-date decline of nearly 20 percent. The medical technology group is currently viewed as being in a transition phase by analysts at RBC Capital Markets, who cite a recent cyberattack and softer demand in specific product lines like orthopedics and peripheral vascular devices as primary headwinds. Despite the near-term caution, the consensus outlook remains constructive for 2027. Analysts anticipate that hospital equipment budgets and surgery schedules will become more predictable later this year, potentially unlocking growth. Currently, Stryker trades at an average analyst price target of USD 374.88, implying a potential upside of approximately 31.65 percent if the company successfully navigates its current challenges. Market data indicates mixed short-term sentiment with shares gaining about 4.17 percent over the last five trading days but remaining down roughly 20 percent since the start of 2026. The stock recently traded intraday around USD 282.23 on the New York Stock Exchange, reflecting modest profit-taking after recent gains in the mid-USD 280 range. The company maintains a market capitalization of approximately USD 106 billion within the healthcare equipment and supplies sector. While RBC flags limited upside for the remainder of 2026, the broader analyst consensus of 28 covers suggests a Buy rating, positioning the current share price as a consolidation zone rather than a definitive turning point.